Montelukast found to be Efficient in preventing seasonal rec
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Vernal keratoconjunctivitis is an allergic inflammation of the eyes that occurs year-round but is aggravated by the seasons. The aim of this study is to see how Effective and Safe oral montelukast is at treating vernal keratoconjunctivitis in children.

This is a 26-week, prospective, randomized, open-label study. 58 patients were randomly assigned to two groups—the treatment (montelukast) and control groups. At the beginning of the study, both the groups received topical loteprednol etabonate (0.1%) in tapering doses for a month, and topical olopatadine (0.1%) for the first 3 months.

Symptoms and signs observed before and after treatment and assigned scores were studied. The primary efficacy endpoint was change in the mean score on the visual analog scale (VAS) for each subjective symptom. The secondary efficacy endpoint was change in the total score of objective signs.

--The montelukast group showed clinically relevant improvements in the signs and symptoms of vernal keratoconjunctivitis, compared to the control group.

--There was considerable improvement in clinical signs. Individual symptoms such as redness, itching, foreign body sensation, and tearing showed significant improvement at 6 months follow-up.

--The gradual improvement in symptoms until the last visit was statistically more significant within montelukast group.

--Mean VAS score showed statistically significant improvement in itching and redness in montelukast group even at 3 months. No adverse events were reported in either group.

Finally, Montelukast was found to be a safe and successful long-term treatment for mild to serious vernal keratoconjunctivitis relapse prevention.